TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02344381

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Study: NCT04432233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: antibiotic for H. pylori eradication
Study: NCT02442063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 dichloride (Xofigo, BAY88-8223)
Description: 50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1
Study: NCT00486603

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation during the first six weeks of treatment Monday-Friday
Study: NCT00536068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid, acetaminophen, diclofenac, naproxen, placebo
Description: 1. Acetylsalicylic acid 100mg/po and acetaminophen 3x1g/po for 4 days~2. Acetylsalicylic acid 100mg/po and diclofenac 3x50mg/po for 4 days~3. Acetylsalicylic acid 100mg/po and naproxen 3x250mg/po for 4 days~4. Acetylsalicylic acid 100mg/po and placebo 3x1/po for 4 days
Study: NCT01421277

Intervention type: DRUG
Intervention: Statin Therapy
Description: Investigator's choice of any statin.

Intervention type: DRUG
Intervention: Statin Therapy
Description: Investigator's choice of any statin.
Study: NCT00813592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230B
Description: SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
Study: NCT02553564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist driven clinical encounter after hospital discharge
Description: Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:~1. The participants's hospital course will be reviewed and their clinical recovery and stability assessed.~2. Determination of the participants's estimated dry weight (EDW).~3. The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.~4. Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.~5. Write new dialysis orders.~6. Dialysis Access- review access and determine any changes required in treatment
Study: NCT03105141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to a given pressure followed by deflation, twice daily for 12 months.~Two different magnitude of limb ischemia pressure will be set: 200 mmHg and 40 mmHg above systolic pressure (60 patients for each).~Optimal inflating pressure will be determined based on the results.
Study: NCT04831008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Figure-of-eight suture
Description: Using the figure-of-eight closure technique when closing access for structural heart therapies.
Study: NCT03105141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning is composed of a given cycle of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The number of cycles of limb ischemia will be set as: 4, 5 and 6 (60 patients for each).~Optimal cycles for application will be determined based on the results.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning is composed of 5 cycles of a given duration of bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The duration of each cycle for limb ischemia will be set as: 4, 5 and 6-min (60 patients for each).~Ischemia duration algorithm will be determined based on the results.
Study: NCT00486603

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation during the first six weeks of treatment Monday-Friday

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation during the first six weeks of treatment Monday-Friday

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation during the first six weeks of treatment Monday-Friday
Study: NCT01734343

Intervention type: DEVICE
Group type: OTHER
Intervention: HOYA iMics Y-60H
Description: same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye

Intervention type: DEVICE
Group type: OTHER
Intervention: PhysIOL microAY
Description: same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
Study: NCT02786901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate Ophthalmic Gel dosed TID
Description: Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate Ophthalmic Gel dosed BID
Description: Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Gel
Study: NCT00037648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: anakinra

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03766243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure and DVD plus nursing training
Description: After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD.~The experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. For both groups an information brochure and an audio-visual DVD were developed specifically for the study. The audio-visual DVD is available on the IDI-IRCCS institutional website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brochure and DVD only
Description: After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD.
Study: NCT01569633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metclopramide
Description: Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Dose of erythromycin is 1 miligram per kilogram every eight hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The dose of sugar water is 1 ml per 8 hours.
Study: NCT03105141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, once or twice daily for 12 months.~The method for application will be set as: once daily for 12 months and twice daily for 12 months (60 patients for each).
Study: NCT01779544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention, an educational model
Description: The goal of the the brief intervention is to provide the patient knowledge to reduce uncertainty so that he or she can understand what is important after lumbar disc surgery so that belief in self-efficacy increases.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention, an educational model
Description: The goal of the the brief intervention is to provide the patient knowledge to reduce uncertainty so that he or she can understand what is important after lumbar disc surgery so that belief in self-efficacy increases.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Patients are instructed to do prescribed exercises the first 3 months after surgery, and to log when they do these
Study: NCT00909662

Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Description: 1. Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~2. Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~3. Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~4. Borg 15-Category Scale

Intervention type: PROCEDURE
Intervention: assessment of therapy complications
Description: 1. Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~2. Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~3. Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~4. Borg 15-Category Scale

Intervention type: PROCEDURE
Intervention: cognitive assessment
Description: Cognitive Task (2 timed 2-minute tests) with Concomitant EEG

Intervention type: PROCEDURE
Intervention: cognitive assessment
Description: Cognitive Task (2 timed 2-minute tests) with Concomitant EEG

Intervention type: PROCEDURE
Intervention: fatigue assessment and management
Description: 1. Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~2. Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~3. Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~4. Borg 15-Category Scale

Intervention type: PROCEDURE
Intervention: fatigue assessment and management
Description: 1. Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~2. Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~3. Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~4. Borg 15-Category Scale
Study: NCT00717405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv 3 weekly in cycles 1-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: 8mg/kg iv loading dose followed by 6mg/kg iv 3 weekly in cycles 5-8.
Study: NCT01401647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiodarone
Description: 300 mg will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 150 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 150 mg, followed by a second dose of 150 mg if the VF/pulseless VT persists.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 120 mg will be given IV/IO push with reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 60 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 60 mg, followed by a second dose of 60 mg if the VF/pulseless VT persists.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 6 cc of normal saline (NS) will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 3 cc will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 3 cc, followed by a second dose of 3 cc if the VF/pulseless VT persists.
Study: NCT01232647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phylloquinone
Description: 1.0 mg daily of vitamin K1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menatetrenone (MK4)
Description: Menatetrenone (MK4) 45 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo vitamin K1 and placebo MK4 given daily for 18 months
Study: NCT04417933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Electric Fields Treatment System
Description: Patients wear two pairs of electrodes on the head for 19-22 hours a day. Each patient is required to wear the device as long as possible and not less than 6 months. The treatment has a two-day break for every four weeks.
Study: NCT00208403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acryloc™ GHV
Description: A high viscosity bone cement for use in total hip replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palacos R
Description: A high viscosity bone cement for use in total hip replacement
Study: NCT01310647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CombEq
Description: (150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.~Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle.
Study: NCT00473330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Sterile solution for intravitreal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Sterile solution for intravitreal injection.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Study: NCT03837249

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal Sleep Monitoring
Description: Wearable Sleep Self-Monitoring Device (Actigraphy)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Personal Sleep Monitoring
Description: Wearable Sleep Self-Monitoring Device (Actigraphy)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal Sleep Monitoring
Description: Wearable Sleep Self-Monitoring Device (Actigraphy)
Study: NCT04831008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perclose Device
Description: Using the Perclose device when closing access for structural heart therapies.
Study: NCT02054845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body awareness therapy
Description: Experimental condition: BEWARE training group The physical and psychosocial elements of the training sessions will be complementary: psychological techniques are used to induce and endure wearing-off and physical techniques are used to improve body awareness to cope with the off-periods.~Specifically the following techniques will be applied:~1. Body scan~2. Psychoeducation~3. Acceptance Commitment Therapy / Mindfulness skills (sustained attention, concentration, non-reactivity, nonjudging of experience)~4. Body Awareness Training~5. Exposure training (imaginary exposure to induce response fluctuations)~6. Training in cueing techniques to overcome problems with initiation and freezing~7. Visual Feedback training~8. Relaxation techniques

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Control condition: Treatment as Usual The control group will receive treatment as usual based on the current guidelines for physical therapy in patients with Parkinson's Disease, with the same training schedule of 2x per week for 1,5 hours during 6 weeks. Group treatment will contain exercises for balance, walking, posture, transfers, arm/hand dexterity, strength, flexibility, relaxation and physical condition.
Study: NCT02847650

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06649751
Study: NCT04535830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flash Glucose Monitoring System
Description: During the three months experimental period,participants at the FSL group will be asked to wear a flash glucose monitoring sensor for a period of 2 weeks and have a care visit every month while people at SMBG group will receive a care visit every month.
Study: NCT01098786

Intervention type: BIOLOGICAL
Intervention: Cell-derived A/H1N1 influenza HA vaccine
Description: Single group vaccinated
Study: NCT02071108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Lithoplasty System
Study: NCT01751113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol
Description: 250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium bromide
Description: 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate/salmeterol plus tiotropium bromide
Description: 250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
Study: NCT03610035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT189
Description: IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
Study: NCT03603015

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Penile cuff test
Description: Comparison of invasive vs non-invasive urodynamics
Study: NCT03162757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheterization
Description: Central venous catheterization via either internal jugular vein or subclavian vein up to a maximum of two attempts.
Study: NCT03610035

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02252250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic total mesentery excision
Description: conventional laparoscopic total mesentery excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transanal hybrid-laparoscopic total mesentery excision
Description: transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
Study: NCT02640521

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chart Reminders & New York State Quit line referral system
Description: Investigators at New York University Medical School, Bellevue and Lincoln Hospital will work closely to (1) develop chart reminders appropriate for each of their clinics (2) to prompt providers to ask about in home smoking at every medical visit and (3) to establish a New York Quit line referral system in the pediatric practice, including clearly defined roles and responsibilities for each step. The New York State Quit line service includes proactive telephone calls with mailings of self-help material, free nicotine replacement therapy for those who qualify, and referrals to local treatment programs, ensuring that health literacy levels of materials is maximized, amending the training curriculum for providers as necessary, and modifying patient education materials that are part of the provider tool kit to focus on the negative impact of secondhand smoke.
Study: NCT03727828

Intervention type: DIAGNOSTIC_TEST
Intervention: Patients with heart failure
Description: Participants will have serial blood collection on medical therapy for heart failure
Study: NCT02227186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-located Influenza Vaccination Clinic
Description: Children in the intervention arm are enrolled in schools in Monroe County, NY that are offering school-located influenza vaccination clinics during school hours
Study: NCT01082523

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text message reminders
Description: Subjects in this arm will receive twice daily automated text messages reminding them to apply their medications.
Study: NCT02080845

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: no caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: no theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low theobromine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high theobromine